The Congressionally Directed Medical Research Programs (CDMRP) have announced their research funding opportunities for fiscal year 2022. Here’s an overview of the breast cancer research funding opportunities. Learn more about these awards and others in our upcoming webinar, Wednesday, March 30, 2022, 1 PM (Eastern).
BioTrinity is an established, must-attend London conference, that catalyses growth and supports in-person re-engagement across the life sciences industry.
The event is attended by an audience of early stage and emerging life sciences R&D Companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions.
The Longevity Leaders World Congress brings the world’s most prominent regenerative medicine and longevity scientists together, presenting the new research, responsible drug development, novel therapies and commercialisation to target age-related diseases.
President Biden called on Congress to fund the creation of a new agency, a DARPA for Health. Some breakthrough ideas don’t receive sufficient attention because they are too high-risk, high-cost, or long-term, because they don’t fit well into academia or the commercial sector, or because they require complex collaborations. The Advanced Research Projects Agency for Health (ARPA-H) aims to support promising opportunities which concern health but which fall in that gap. ARPA-H will not have intramural labs. It will facilitate research directed at solving practical problems. To date, the kinds of non-dilutive funding opportunities which will be available through ARPA-H (grants, contracts, etc.) have not been defined, but we can make intelligent guesses.
Spending bill ends funding for Biden’s COVID-19 programs, including some R&D, but does provide more funding for biomedical research: $45 billion for NIH, including $1 billion for Advanced Research Projects Agency for Health (ARPA-H), and $8.5 billion for the CDC.
Premier conference for ATMP community in Europe and beyond
Bio-Europe Spring is the most international biopharma industry gathering this spring. Delivered virtually, March 28-31, 2022, with over 2,700 assets posted, 60% biopharma attendance, 50+ countries expected to attend, and 1:1 meetings via the partneringONE® system.
The 5th Annual Neuroscience Innovation Forum (NIF) will take place on the 22nd – 23rd of March 2022, with 1:1 meetings 21st – 25th of March during which the online meeting system open for 12 hours a day.
The main programme for the 5th Annual NIF will be spread throughout 2 days. Featuring more than 12 hours of high-level keynotes, panel discussions, and spotlight showcases. The target audience for this event are buy and sell-side analysts from investment banks and funds, as well as partnering executives from pharma, biotech, digital therapeutics and neurotech companies. We anticipate 300+ delegates and 35+ company presentations by established listed, private and growth companies.
The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health (4 Ds). RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare.